Abstract
Aberrant expression of microRNAs (miRNAs) has been causatively linked to multiple disease pathologies while pharmacological inhibition of overexpressed miRNAs by modified oligonucleotides, termed anti-miRs, has been shown to ameliorate the disease phenotype. Anti-miRs are also widely used in academia to define miRNA-mediated regulation of gene networks in vitro and in vivo. Here, we describe a methodology that allows the determination of the physical association of miRNA inhibitors and their targets in the context of the Argonaute complex in vivo, providing unprecedented insight into the physiological interactions of anti-miRs and the miRNA machinery.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ambros V, Moss EG (1994) Heterochronic genes and the temporal control of C. elegans development. Trends Genet 10:123–127
Gottlieb S, Ruvkun G (1994) daf-2, daf-16 and daf-23: genetically interacting genes controlling Dauer formation in Caenorhabditis elegans. Genetics 137:107–120
Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI et al (2000) Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408:86–89
Alvarez-Garcia I, Miska EA (2005) MicroRNA functions in animal development and human disease. Development 132:4653–4662
Soifer HS, Rossi JJ, Saetrom P (2007) MicroRNAs in disease and potential therapeutic applications. Mol Ther 15:2070–2079
Hutvagner G, Simard MJ, Mello CC, Zamore PD (2004) Sequence-specific inhibition of small RNA function. PLoS Biol 2, E98
Meister G, Landthaler M, Dorsett Y, Tuschl T (2004) Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 10:544–550
Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309:1577–1581
Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T et al (2005) Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438:685–689
Davis S, Lollo B, Freier S, Esau C (2006) Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res 34:2294–2304
Esau C, Davis S, Murray SF, Yu XX, Pandey SK et al (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3:87–98
Janssen HL, Kauppinen S, Hodges MR (2013) HCV infection and miravirsen. N Engl J Med 369:878
Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M et al (2013) Treatment of HCV infection by targeting microRNA. N Engl J Med 368:1685–1694
Van Der Ree MLV, Stelma F, Willemse S, van der Valk M, Rietdijk S, Molenkamp R, Schinkel J et al (2015) A single subcutaneous dose of 2 mg/kg or 4 mg/kg of RG-101, a GalNAc-conjugated oligonucleotide with antagonist activity against MIR-122, results in significant viral load reductions in chronic hepatitis C patients. J Hepatol 62:S261
Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233
Esau CC (2008) Inhibition of microRNA with antisense oligonucleotides. Methods 44:55–60
Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S (2012) Inhibition of microRNA function by antimiR oligonucleotides. Silence 3:1
Crooke ST (2008) Antisense drug technology: principles, strategies, and applications. CRC Press, Boca Raton, FL, xvii, 825 p, 812 p. of plates p
Davis S, Propp S, Freier SM, Jones LE, Serra MJ et al (2009) Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res 37:70–77
Torres AG, Fabani MM, Vigorito E, Gait MJ (2011) MicroRNA fate upon targeting with anti-miRNA oligonucleotides as revealed by an improved Northern-blot-based method for miRNA detection. RNA 17:933–943
Hogan DJ, Vincent TM, Fish S, Marcusson EG, Bhat B et al (2014) Anti-miRs competitively inhibit microRNAs in Argonaute complexes. PLoS One 9:e100951
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Zisoulis, D.G. (2017). Determination of Anti-miR Association with miRNA/Argonaute Complexes In Vivo. In: Schmidt, M. (eds) Drug Target miRNA. Methods in Molecular Biology, vol 1517. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6563-2_5
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6563-2_5
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6561-8
Online ISBN: 978-1-4939-6563-2
eBook Packages: Springer Protocols